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Methicillin-resistant Staphylococcus aureus (MRSA)
infections constitute a serious health threat world-
wide, and novel antibiotics are therefore urgently
needed. The enoyl-ACP reductase (saFabI) is essen-
tial for the S. aureus fatty acid biosynthesis and,
hence, serves as an attractive drug target. We have
obtained a series of snapshots of this enzyme that
provide a mechanistic picture of ligand and inhibitor
binding, including a dimer-tetramer transition com-
bined with extensive conformational changes.
Significantly, our results reveal key differences in
ligand binding and recognition compared to ortholo-
gous proteins. The remarkable observed protein
flexibility rationalizes our finding that saFabI is
capable of efficiently reducing branched-chain fatty
acid precursors. Importantly, branched-chain fatty
acids represent a major fraction of the S. aureus
cell membrane and are crucial for its in vivo fitness.
Our discovery thus addresses a long-standing
controversy regarding the essentiality of the fatty
acid biosynthesis pathway in S. aureus rationalizing
saFabI as a drug target.
INTRODUCTION
Resistant strains of the gram-positive human pathogen Staphy-
lococcus aureus emerged only two years after the introduction of
the antibiotic methicillin in 1959. Since then, methicillin-resistant
S. aureus (MRSA) infections have become an increasing problem
in hospitals worldwide. To treat severe MRSA infections, vanco-
mycin is currently used as the drug of last resort (Pantosti and
Venditti, 2009). Thus, the initial occurrence of a vancomycin-
resistant S. aureus (VRSA) strain in June 2002 is especially
alarming (Sievert et al., 2008). Unfortunately, antibiotic resis-
tance has drastically outpaced new antibiotic discovery, which
flourished between the 1940s and 1960s. Between 1962 and
2000, only a few novel scaffolds, such as the carbapenems,802 Structure 20, 802–813, May 9, 2012 ª2012 Elsevier Ltd All rightswere approved, and novel antibiotics with alternative modes of
actions are therefore urgently needed. Accordingly, from 2000
onward, oxazolidinones (e.g., linezolid), the lipopeptide dapto-
mycin, and the mutilins were introduced (Fischbach and Walsh,
2009).
One strategy that targets the bacterial cell envelope involves
the inhibition of the type II fatty acid biosynthesis pathway
(FAS II), which is responsible for the de novo production of phos-
pholipid precursor molecules (Payne et al., 2002). In contrast to
the large multifunctional mammalian FAS I synthase, the FAS II
system of bacteria, protozoa, and plants consists of individual
monofunctional enzymes, allowing selective inhibition (Payne
et al., 2001). In this pathway, the fatty acid chain, which is
attached to the acyl carrier protein (ACP), is elongated by two
carbon atoms per cycle (Figure 1). The final reduction is cata-
lyzed by the NAD(P)H-dependent trans-2-enoyl-ACP reductase
(FabI), which is known to play a key regulatory role in this
pathway (Heath and Rock, 1995; Xu et al., 2008). This enzyme
is highly conserved across many pathogens; however, the
S. aureus enoyl-ACP reductase (saFabI) is the only known FabI
with a clear preference for NADPH (Heath et al., 2000; Priyadar-
shi et al., 2010; White et al., 2005; Xu et al., 2008). The clinical
success of FabI inhibitors, such as the first-line tuberculosis pro-
drug isoniazid (Lu and Tonge, 2008) and several compounds
currently in phase I clinical trials (Gerusz, 2010), validates this
enzyme as an attractive drug target. Furthermore, the FabI
diphenyl ether inhibitor triclosan (TCL) is recommended as
topical antiseptic to reduce MRSA skin colonization (Bamber
and Neal, 1999).
Recently, however, Brinster et al. (2009) challenged the validity
of FAS II inhibitors because Streptococcus agalactiae can utilize
exogenous fatty acids from the host blood serum to survive
inhibition of its FAS II machinery. Whether this resistance mech-
anism extends to all gram-positive bacteria including S. aureus is
currently controversially discussed (Balemans et al., 2010;
Parsons et al., 2011). Importantly, S. aureus remains sensitive
to FabI inhibitors in vivo, as shown in several rodent models
(Balemans et al., 2010; Escaich et al., 2011; Park et al., 2007;
Payne et al., 2002).
To investigate the suitability of saFabI as a drug target, we
have structurally and biochemically characterized this enzyme
with respect to inhibitor binding, conformational flexibility, ligandreserved
Figure 1. The Bacterial Type II Fatty Acid Biosynthesis Pathway as a Drug Target
S. aureus enzymes are shown in red, while isoforms in other organisms are depicted in black (Payne et al., 2001). Initiation of fatty acid biosynthesis requires
malonyl-ACP, which is formed from acetyl-CoA by acetyl-CoA carboxylase (Acc) and malonyl-CoA:ACP transacylase (FabD). The b-ketoacyl-ACP synthase
FabH (KAS III) performs the first Claisen condensation yielding a b-ketoacyl-ACP from malonyl-ACP and an acyl-CoA primer. The two carbons originating from
malonyl-ACP are shown in cyan and the first two primer carbons are shown in red. Subsequently, the b-ketoacyl-ACP is converted to a saturated acyl-ACP by the
actions of the NADPH-dependent reductase FabG, the dehydrase FabZ, and the mostly NADH-dependent enzyme FabI. The saturated acyl-ACP is a substrate
for additional rounds of elongation in which FabF catalyzes the condensation reaction. The long-chain acyl-ACP products are subsequently partially transformed
into membrane lipids (a typical S. aureus phosphatidylglycerol is shown; Parsons et al., 2011). Most bacteria use acetyl-CoA as the primer, which results in
straight-chain fatty acids (C14 and C16) (Mendoza et al., 2002); however, S. aureus FabH prefers branched-chain acyl-CoAs, which yield branched-chain fatty
acids (Qiu et al., 2005). The branched-chain primers isobutyryl-CoA, isovaleryl-CoA, and 2-methylbutyryl-CoA are derived from valine, leucine, and isoleucine,
respectively, through the actions of the branched-chain aminotransferase BAT (ilvE; Madsen et al., 2002), and the branched-chain a-ketoacid dehydrogenase
BKD (lpd, bkdA1, bkdA2, and bkdB; Singh et al., 2008). The branched-chain acyl-CoAs yield iso-C14 and iso-C16 (isobutyryl), iso-C15 and iso-C17 (isovaleryl), as
well as anteiso-C15 and anteiso-C17 (2-methylbutyryl) fatty acids (Mendoza et al., 2002). Exogenous fatty acids are converted into acyl-ACPs by the acyl-ACP
synthetase (AAS) for incorporation into cell membranes. Typical fatty acids of the human blood plasma are palmitic (21.3%) and linoleic acid (23.7%) (Holman
et al., 1995). For S. aureus, exogenous oleic acid was only incorporated in the 1-position of phosphatidylglycerol (Parsons et al., 2011). Inhibitors of the NADPH-
dependent FabI from S. aureus (saFabI) used in this study include 5-chloro-2-(2,4-dichlorophenoxy)phenol (triclosan), 5-chloro-2-phenoxyphenol (CPP), and 5-
ethyl-2-phenoxyphenol (EPP) (Xu et al., 2008), shown in the box on the left.
See also Figure S1.
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Substrate and Inhibitor Recognition by saFabIbinding mechanism, cofactor and substrate specificity, quater-
nary structure, and cooperativity. We identified significant
differences in the S. aureus and Bacillus FabIs compared to
the classical FabI proteins from organisms such as Escherichia
coli, Burkholderia pseudomallei, and Francisella tularensis and
in our structures with respect to the recently determined
S. aureus FabI structures in complex with triclosan and in its
apo-state (Priyadarshi et al., 2010). Importantly, our analysis
revealed that the substrate specificity of saFabI displays an
increased specificity for branched-chain (BCFA) relative to
straight-chain fatty acid (SCFA) precursors (Figure S1 available
online), consistent with the high content of BCFAs in the mem-
branes of staphylococci and bacilli (Kaneda, 1991). Because
BCFAs, which are barely found in human serum (Holman et al.,Structure 201995), are likely required for S. aureus fitness in vivo, we
conclude that saFabI is a suitable target for drug discovery.
RESULTS
Overall Structure
To provide a molecular basis for the rational design of
compounds that target saFabI, we solved the structures of
ternary FabI complexes with the cofactor NADP+ and the
diphenyl ether inhibitors triclosan (TCL), 5-chloro-2-phenoxy-
phenol (CPP), or 5-ethyl-2-phenoxyphenol (EPP), respectively
(Figure 1 and Figures S1 and S2). As a member of the short-
chain dehydrogenase/reductase (SDR) superfamily, saFabI
contains an extended Rossmann-fold composed of a central, 802–813, May 9, 2012 ª2012 Elsevier Ltd All rights reserved 803
Figure 2. Overall Structure and Flexibility of saFabI
(A) Homo-tetrameric structure of saFabI. Each subunit of the TCL-2 structure is shown in a different color. The three perpendicular 2-fold noncrystallographic
symmetry axes P, Q, and R are indicated. The interfaces spanned by the axes P and R (Q and R) are referred to as the PR-interface (QR-interface).
(B) Structure of the saFabI monomer. a Helices are shown in red, b strands in yellow, loops in green, and cofactor and inhibitor as space-filling models. The
chairlike structure consists of the Rossmann-fold (seat, lower part) and the active site (back, upper part).
(C) Flexibility of the saFabI active site in its ligand-free form. Multi-rmsd values were calculated for the Ca atoms of the apo-1 (one subunit), apo-2 (all subunits),
and TCL-2 (one subunit) structures using LSQMAN (Kleywegt and Jones, 1996). These values varied from 0.2 to 20.5 A˚ and are represented by color (from blue to
red) and width of the TCL-2 model (residues 2-256). Rmsd-values for the missing residues 199–201 were interpolated in a linear fashion based on the values for
the two adjacent amino acids 198 and 202.
See also Figure S2.
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Substrate and Inhibitor Recognition by saFabIseven-stranded parallel b sheet surrounded by three a helices on
either side (Figure 2B) (Grimm et al., 2000; Lu and Tonge, 2008).
Furthermore, the structures of our saFabI inhibitor complexes
clearly show the presence of homo-tetramers (Figure 2A), as
observed in other organisms (White et al., 2005). The closest
relationship is foundwith the FabI structures from the gram-posi-
tive organisms Bacillus anthracis and B. subtilis, as well as with
the incorrectly designated ‘‘FabL’’ from B. cereus, which is
100% identical to B. anthracis FabI (Figure 3).
In addition, we solved two apo saFabI structures that display
unexpected flexibility in close proximity to the substrate binding
site (Figure 2C). In one of the two apo structures, all four mono-
mers (apo-2; nomenclature of all structures according to Tables
S1 and S2) differ in their active site (pairwise rmsd of 0.84 A˚) and
display conformations that, to our knowledge, have never been
observed before. Compared to the inhibitor-bound complexes,
three regions—the active site and two substrate-binding loops
(Figure 3)—are either disordered or visible in a rearranged archi-
tecture. In contrast, previously published apo structures of FabI
proteins from gram-negative bacteria (Protein data Bank [PDB]
codes 2JJY, 2P91, 2WYU, 3EK2, 3GRK, and 3K2E) show
disorder in only one region, the substrate-binding loop.
SaFabI Inhibition
In contrast to the previously described saFabI-NADP+-TCL
structure (PDB code 3GR6) (Priyadarshi et al., 2010), our high-
resolution saFabI complex structures with the unsymmetrically
substituted inhibitors EPPandCPPunequivocally reveal a similar
binding mode of diphenyl ethers including triclosan to saFabI, as
reported for homologous FabI proteins (Lu and Tonge, 2008; Xu
et al., 2008), which allows the formation of two key hydrogen
bonds connecting the A-ring hydroxyl group to Tyr157 and to
the 20-OH of the nicotinamide ribose at 2.5 ± 0.1 and 2.6 ±
0.1 A˚, respectively (Figure 4B). TCL, CPP, and EPP bind to
a pocket composed of NADP+ and several mainly hydrophobic
residues with average distances of 3.8 ± 0.4 A˚ (Figures 4B and804 Structure 20, 802–813, May 9, 2012 ª2012 Elsevier Ltd All rights4C). Notably, the carbonyl oxygen of Ala97 forms a geometrically
favorable halogen bond (Bissantz et al., 2010) with the TCL
B-ring chlorine at position 4 (3.2 ± 0.1 A˚). At the same time the
chlorine is weakly hydrogen bonded to the amide NH group of
Ala97 (3.2 ± 0.1 A˚, Figure 4B). Accordingly, TCL exhibits an
almost 3-fold lower Ki*
,app value as compared to CPP, which
lacks the two B-ring chlorines and is rotated by 11 ± 2 into
the binding crevice (Table 1, Figure 4D, and Supplemental
Results).
Induced Fit Ligand Binding
SaFabI undergoes several major conformational changes upon
cofactor and inhibitor binding, which have, to our knowledge,
never been observed previously for its gram-negative FabI or-
thologs, thus allowing us to describe a fundamentally expanded
mechanism for ligand binding. All residues interacting with the
diphenyl ether inhibitors are located in three distinct regions (Fig-
ure 3), which exhibit substantial flexibility prior to cofactor and
inhibitor binding. As described for numerous FabI orthologs
and other SDR proteins, the substrate-binding loop (SBL,
194–204) is disordered or rearranged in our apo structures
(Grimm et al., 2000; Tipparaju et al., 2008). In contrast to other
FabI structures, however, the saFabI structures reveal flexibility
of a second substrate-binding loop (SBL-2, 94–108) as well as
the active site loop (ASL, 147–157).
Superposition of the apo-1 structure with TCL-2 shows that
the active site is wide open prior to cofactor and inhibitor or
substrate binding (Figure 5A). In addition to the three aforemen-
tioned loop regions, the C-terminal SBL extension a7 is disor-
dered. The apo-2 structure provides informative snapshots of
the motion of a7 on its way to the ternary complex conformation
because every subunit shows a different arrangement of this
helix (Figures 5B–5F and Movie S1). In one subunit, this helix is
shifted 13 A˚ away from the active site (Figure 5B). When helix
a7 moves toward the protein core, it is still rotated about 105
relative to the ternary complex conformation (Figure 5C) andreserved
Figure 3. Secondary Structure of saFabI and Alignment with Similar Proteins
Secondary structure matching (SSM) was performed for the TCL-2 structure using PDBe Fold (Krissinel and Henrick, 2004). The secondary structure of saFabI is
shown in the first line according to the program DSSP (Kabsch and Sander, 1983). Secondary structure elements participating in the QR and PR-interfaces are
depicted in red and blue, respectively. Amino acids highlighted in red are conserved. The alignment comprises the seven best SSM hits (Q-scores are indicated
behind the sequences) including bsFabL and saFabG. The first two letters of the protein names indicate the bacterial source (sa = S. aureus, ba = Bacillus
anthracis, bc = B. cereus, bs = B. subtilis, ft = Francisella tularensis, tt = Thermus thermophilus, ec = Escherichia coli, and aa = Aquifex aeolicus). PDB codes and
subunits are given in parentheses. Blue, red, and cyan stars mark residues interacting with the cofactor, inhibitor, or cofactor and inhibitor, respectively.
Disordered or rearranged regions in all four available saFabI apo structures (apo-1, apo-2, 3GNS, and 3GNT) are marked with a continuous line, and regions that
are additionally disordered or rearranged for distinct apo structures are represented by a dashed line. This figure was prepared with ESPript (Gouet et al., 1999).
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Substrate and Inhibitor Recognition by saFabIassumes its final conformation via rotation angles of 70 and
20 (Figures 5D–5F). Intermittently, the adjacent helix a8 is elon-
gated by up to two turns (Figure 5C and 5D). Finally, the N-termi-
nally attached SBL closes upon actual cofactor and inhibitor
binding.
During this process, the ASL is visible inside the ligand-binding
pocket (Figure 5D) and SBL-2 adopts an entirely a-helical
conformation (Figure 5B). Subsequently, SBL-2 is split into the
310-helices h2 and h3 and adopts a more open conformation
(Figures 5D and 5G). A comparison with the ternary complex
structure TCL-2 shows that a backbone flip of Ala95 propagates
the movements of adjacent residues and leads to the subse-
quent closure of SBL-2 (Figure 5G). This peptide flip may be
induced by the ordering of Ser197 located on the SBL, which
allows the formation of a water-mediated hydrogen bond
interaction with the carbonyl oxygen of Ala95. Simultaneously,
the movement of Phe96 creates space for the binding of the
TCL B-ring and establishes an elongated acyl-channel. During
NADP+ binding, a similar peptide flip mechanism was observedStructure 20for the NADPH-dependent b-ketoacyl-ACP reductase ecFabG,
which also belongs to the SDR family of proteins (Price et al.,
2004).
We speculate that the concerted closure of both SBLs, instead
of just the classical SBL, is the conformational change corre-
sponding to the slow step of the slow-binding inhibition (Lu
and Tonge, 2008). On the basis of sequence similarities, this
mechanism should mainly be feasible for staphylococci, several
bacilli, and some Listeria strains because they contain a serine at
position 197, which connects the SBLs (Figure 5G). Most other
gram-negative and gram-positive bacteria harbor an alanine at
this position and, thus, lack the required hydrogen bond
acceptor (Figure 3). Consistently, all structurally characterized
FabIs from gram-negative organisms contain just a single flex-
ible SBL (PDB codes 2JJY, 2P91, 2WYU, 3EK2, 3GRK, and
3K2E), as opposed to Bacillus FabIs (3OIF and 3OJE) and the
related proteins bsFabL (3OIC) and ecFabG (1I01), which all
feature three disordered or rearranged regions in their apo
structure., 802–813, May 9, 2012 ª2012 Elsevier Ltd All rights reserved 805
Table 1. Potency of saFabI Inhibition by Diphenyl Ether Analogs
Inhibitor Ki*
,app (nM)
CPP 161.2 ± 8.4
EPP 106.6 ± 7.9
Triclosan 60.9 ± 5.6
Figure 4. SaFabI Inhibition with Diphenyl Ethers
(A) Dose-response curves of diphenyl ether analogs. The steady-state reaction velocities (vs) at various inhibitor (CPP, EPP, and triclosan) concentrations are
plotted as a fraction of the uninhibited reaction velocity (vu). Each plot is fitted to the standard binding isotherm. R
2 = 0.88, 0.75 and 0.73 for the best fit curves to
the binding isotherm for CPP, EPP, and triclosan, respectively.
(B) Schematic representation of all residues interacting with triclosan (TCL in red). The interaction pattern was derived from the TCL-2 structure. Directional
interactions are depicted explicitly (black residues), and amino acids creating the hydrophobic pocket are included in 1-letter code (residues in blue boxes).
R = adenosine diphosphate.
(C) Fit of triclosan in its binding pocket. Triclosan is shown as space fillingmodel in gray. Ala95, Phe96, Ala97, Leu102, Tyr147, Tyr157,Met160, Ile207, andNADP+
are shown in surface representation in blue. Additionally interacting residues Ser197, Ala198, Val201, and Phe204 are located within the substrate-binding
loop (SBL).
(D) Comparison of the TCL and CPP inhibitor binding modes. The TCL-2 structure is shown in gray and yellow, and the CPP structure is shown in blue. The
cofactor and some protein regions are omitted for clarity. Arrows indicate differences between the two structures. The B-ring is rotated by11 ± 2 upon removal
of the two chlorine atoms. Simultaneously, the Ca atoms of Ala97, Leu102, Ser197, and Ala198 move toward the inhibitor by about 0.4 ± 0.1 A˚, 0.3 ± 0.1 A˚,
0.3 ± 0.1 A˚, and 0.2 ± 0.1 A˚, respectively, and the side chain of Met160 rotates away from the inhibitor by 13 ± 3.
Structure
Substrate and Inhibitor Recognition by saFabIDimer-Tetramer Transition
The apo FabI structures from gram-negative bacteria contain
homo-tetramers, whereas bcFabI/baFabI, in the absence of
cofactor and inhibitor, were reported to be dimers in the crystal
and in solution (Kim et al., 2010). So far, reports regarding the
oligomeric state of saFabI have been inconsistent. It was noted
that the published apo structures of saFabI (3GNS and 3GNT)
are composed of dimers, though the enzyme was found to be
a tetramer in solution (Kim et al., 2010; Priyadarshi et al.,
2010). Therefore two questions arose: What is the oligomeric
state of saFabI prior to ligand binding? If dimers are present,
does tetramerization and active site formation occur in a
concerted fashion with cofactor and inhibitor binding as hypoth-
esized for bsFabL (Kim et al., 2011)?
Our results clearly show that NADP+ and triclosan binding to
dimeric saFabI induces simultaneous active site formation and
tetramerization. In contrast to a previous report but in accor-
dance with the respective apo saFabI structures (3GNS and
3GNT) (Priyadarshi et al., 2010), we identified a dimer through806 Structure 20, 802–813, May 9, 2012 ª2012 Elsevier Ltd All rightsanalytical size exclusion chromatography (SEC) experiments at
pH 8.0 (Figure S3A), whereas tetramers are present at pH 5.6
(see Experimental Procedures for details). We performed further
analytical SEC experiments with the dimeric enzyme in its apo
form or incubated with NADP+, NADPH, or NADP+ and TCL.
Our results unambiguously demonstrate a transition between
dimers and tetramers upon both inhibitor and cofactor binding
(Figure S3B), whereas binding of oxidized or reduced cofactor
alone is not sufficient to induce tetramerization.
A structure and interface analysis of all available saFabI struc-
tures provides snapshots of the dimer-tetramer transition in thereserved
Figure 5. Cofactor and Inhibitor Binding Mechanism
(A–F) Consecutive conformations of saFabI proposed to be adopted during cofactor and inhibitor binding are shown. The three regions undergoing the most
extensive conformational changes are highlighted (SBL-2 in cyan, ASL in dark blue, and the C-terminally extended SBL in red as in Figure 3). One subunit of TCL-2
is continuously shown as a reference in yellow. (A) Superposition of the apo-1 and TCL-2 structures. Apo-1 is shown in light blue. (B–E) Superposition of the apo-2
and TCL-2 structures. Subunits B, C, A, and D of apo-2 are shown in light blue. (F) Final ternary complex conformation. The hydrogen bonded residues Arg194
and Asn205 can act as a hinge for SBL-1 closure and are displayed in a larger scale in the black box (Maity et al., 2011).
(G) Peptide flipmechanism andSBL-2 closure observed upon superposition of TCL-2 (yellow) with apo-2 (light blue, subunit A). The carbonyl oxygen of Ala95 flips
between Ser121 in the apo structure and a water molecule bound to Ser197 in the ternary complex (a rotated view is displayed in the insert).
See also Figure S4 and Movie S1.
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Substrate and Inhibitor Recognition by saFabIorder 3GNT, 3GNS, apo-1, apo-2, and TCL-2 (Figure 6 and
Movie S2). During this process, the buried surface area of the
QR-interface, about which the association occurs, increases
significantly, as does the number of hydrogen bonds and salt
bridges between interface residues (Figure 6C). The QR-inter-
face is established via a 4-helix bundle comprising the long
helices a4/a5 (kinked) and a6 (Figure 6, last column). Addition-
ally, the corresponding N-terminal extensions h3 and h4 further
stabilize this interface (Figure 3). Because the SBL-2 and ASL
regions including these 310-helices are disordered in our apo
structures, the QR-interface is destabilized and the dimers
move slightly (2 A˚) away from one another. During the ordering
of the ASL, the full tetramer interface and the catalytic active site
are simultaneously established (Figure S4). The 3GNS structure
clearly contains dimers because of the additionally disordered
a4 region (Figure 3). This helix is therefore essential for the main-
tenance of the QR-interface. Although helix a6 of 3GNS is almost
completely structured and just slightly shifted, the N-terminal
portion of this helix is unstructured and partially disordered in
3GNT.
Cooperativity
Wehypothesize that the dimer-tetramer transition also applies to
substrate binding, representing themolecular basis for the previ-Structure 20ously reported positive cooperative binding of NADPH to saFabI
(Heath et al., 2000). Our data clearly show that NADPH binds
cooperatively to saFabI with an approximate Hill coefficient
h = 2 (Figure S5). Additionally, trans-2-octenoyl-CoA bound
cooperatively to saFabI with a Hill coefficient h = 2.3. However,
glutamate, which enhances the catalytic activity of the enzyme
(Supplemental Discussion), was found to alter the cooperativity
of binding to saFabI. In the presence of 1 M potassium gluta-
mate, no cooperativity was observed for the binding of NADPH
or trans-2-octenoyl-CoA to saFabI. Because cooperativity was
still observed in the presence of 250 mM potassium glutamate,
which is an upper limit estimate of the average S. aureus intracel-
lular glutamate concentration (Bjo¨rklind and Arvidson, 1978;
Blanche et al., 1996), it is likely to be physiologically relevant.
Mechanistically, the observed positive cooperativity of substrate
binding could be transferred via the ligand-interacting SBL-2 and
ASL regions and the attached long helices a4 and a6, which
primarily constitute the QR-interface. The formation of such an
interface would enhance cofactor and inhibitor/substrate
binding due to the rearrangement of the two loop regions and
vice versa.
Cooperativity has, to our knowledge, never been observed for
NADH-dependent wild-type FabI enzymes, which already exist
as tetramers in their apo forms (Heath et al., 2001). In contrast,, 802–813, May 9, 2012 ª2012 Elsevier Ltd All rights reserved 807
Figure 6. Dimer-Tetramer Transition
From left to right, the QR-interface in the saFabI crystal structures 3GNT, 3GNS (Priyadarshi et al., 2010), apo-1, apo-2, and TCL-2 is shown to illustrate tetramer
association and dissociation (view as in Figure 2A). The two associating dimers are shown in gray and yellowwith the respective QR-interface residues (according
to the PDBe PISA server; Krissinel, 2010) in cyan and red.
(A) Front view of the dimer-tetramer transition.
(B) Side view of the dimer-tetramer transition.
(C) Close-up view of the upper QR-interface half. Buried surface areas of the monomeric QR-interface (BSAQR) as well as the numbers of the corresponding
hydrogen bonds (NHB) and salt bridges (NSB) are given below according to PISA.
See also Figures S3 and S5 as well as Movie S2.
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Substrate and Inhibitor Recognition by saFabIa similar FabI tetramerization process might be possible for
Bacillus species because a4 is additionally disordered in the
dimeric bcFabI/baFabI apo structure (PDB code 3OJE:A) (Kim
et al., 2010). Similarly, the twisted tetramer architecture of the
bsFabL apo structure (3OIC:A) comprises N-terminally shifted
a4 and a6-helices and therefore links this protein to saFabI
(Kim et al., 2011).
Cofactor Specificity
The studies described above reveal fundamental differences
between saFabI and classical FabI proteins. Hence, we also
investigated cofactor specificity because, in contrast to all
gram-negative FabI homologs studied thus far, saFabI prefers
NADPH instead of NADH as the reducing agent (Heath et al.,
2000; White et al., 2005). Our structural analysis confirmed that
the positively charged side chains of Arg40 and Lys41 are
important for binding the additional 20-phosphate of NADPH
(Priyadarshi et al., 2010; Xu et al., 2008) (Figure 7A). However,
we identified an RKXXS-motif that confers this unique specificity
to saFabI. Although the R40Q/K41N saFabI double mutant808 Structure 20, 802–813, May 9, 2012 ª2012 Elsevier Ltd All rightsexhibited a drastically decreased kcat/Km value for NADPH, the
specificity constant remained low for NADH (Xu et al., 2008).
Our structures revealed Ser44 as a third crucial residue for
NADPH specificity. The serine hydroxyl group forms a hydrogen
bond to one of the phosphate oxygen atoms at a distance of
2.9 ± 0.1 A˚, whereas the Ser44-bound phosphate oxygen forms
additional hydrogen bonding interactions with the backbone
amide nitrogens of Arg40 and Lys41, which are located in a tight
loop between b2 and a2 (Figure 7A).
Unlike saFabI, the enoyl-ACP reductase from E. coli (ecFabI) is
NADH-dependent (Stewart et al., 1999). Superposition of saFabI
with ecFabI shows that Leu44 and Gln40 clash with the 20-phos-
phate of a hypothetically bound NADPH (shortest distances of
1.7 ± 0.1 and 1.5 ± 0.2 A˚; Figure 7B). Bulky substituents at posi-
tion 44 (numbers according to saFabI), such as Leu or Phe (Fig-
ure 3), appear to shrink the adenine ribose-binding pocket, thus
decreasing the affinity toward NADPH.
To test the hypothesis that the RKXXS-motif is responsible for
cofactor specificity, we generated a triple mutant with all three
phosphate-interacting amino acids replaced by the respectivereserved
Figure 7. Structural Basis of NADPH Specificity
(A) The 20-phosphate binding motif. NADP+ is shown in gray, and saFabI (CPP
structure) is shown in yellow. Additional parts of the protein are omitted for
clarity.
(B) Superposition of saFabI and ecFabI. SaFabI is shown in yellow, and ecFabI
(1QSG:A) is shown in green. Asn41 is shifted 2.8 ± 0.3 A˚ toward the solvent
compared to Lys41 preventing 20-phosphate stabilization by an Asn41 back-
bone interaction.
Table 2. Kinetic Parameters for saFabI Wild-Type, Double, and
Triple Mutant Utilizing NADPH and NADH at Saturating trans-2-
Octenoyl-CoA Concentrations
Km,NADPH
(mM) kcat (min
1)
kcat/Km,NADPH
(min1 mM1)
wt saFabI 189.4 ± 20.9 2171.2 ± 123.3 11.5 ± 1.4a
saFabI
R40Q/K41N
>300 0.066 ± 0.001b
saFabI R40Q/
K41N/S44L
>300 0.0038 ± 0.0002b
Km,NADH
(mM) kcat (min
1)
kcat/Km,NADH
(min1 mM1)
wt saFabI >300 4.7 ± 0.2b
saFabI
R40Q/K41N
139.8 ± 23.2 1852.1 ± 132.6 13.2 ± 2.4
saFabI R40Q/
K41N/S44L
72.2 ± 26.4 1846.6 ± 266.3 25.6 ± 10.1
Saturating trans-2-Octenoyl-CoA concentration (150 mM).
aAgrees with the linear slope (11.1 ± 0.3) of the Michaelis-Menten plot at
low [NADPH].
bEstimated based on linear slope of the Michaelis-Menten plot at low
[NAD(P)H].
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Substrate and Inhibitor Recognition by saFabIE. coli residues (R40Q/K41N/S44L). Interestingly, compared to
results reported in the absence of glutamate (Xu et al., 2008),
there is only a 2.5-fold increase in the specificity constant of
wild-type saFabI for NADPH relative to NADH in the presence
of glutamate (Table 2). The glutamate-containing conditions
also strongly affected the specificity constant of the R40Q/
K41N mutant for NADH, which recovered to that of the wild-
type enzyme for NADPH. Additionally, the specificity constant
of the double mutant for NADH was 200-fold higher than for
NADPH, compared to the 19-fold difference reported in the
absence of glutamate. The triple mutant displayed an even
more dramatic inversion of cofactor specificity with the speci-
ficity constant for NADPH nearly 10,000-fold lower than for
NADH. This was driven mostly by a decrease in the ability to
utilize NADPH, consistent with our prediction that Leu44 would
clash with the 20-phosphate. Interestingly, the Km,NADPH of
wild-type saFabI is higher than the Km,NADH of the triple mutant
(Table 2 and Table S3) and other FabI homologs (Parikh et al.,
1999; Sivaraman et al., 2003) which correlates well with the esti-
mated higher microbial intracellular pool of NADPH compared to
NADH (Bennett et al., 2009; Liebeke et al., 2010).Structure 20Using BLAST and PHI-BLAST searches (Altschul et al., 1990)
with the newly identified RKXXS-motif, we found that this prefer-
ence for NADPH links saFabI to all Staphylococcus and some
Bacillus FabIs, as well as FabL and FabG, rather than to classical
NADH-dependent FabIs.
Branched-Chain Substrate Specificity
What is the underlying biological significance of the structural
variations we observed for the FabIs from staphylococci and
bacilli? Notably, the membranes of Staphylococcus and Bacillus
genera contain branched-chain fatty acids (BCFA) as a major
component (Kaneda, 1991). In contrast, most other bacteria
(Kaneda, 1991) predominantly synthesize straight-chain fatty
acids (SCFA). For the more common SCFA family members,
membrane fluidity is controlled by unsaturated fatty acids
(UFA), whereas, for BCFA family members, 12-methyltetradeca-
noic acid (anteiso-C15) primarily fulfills this purpose (Kaneda,
1991). Thus, we speculated that the increased mobility of FabI
from staphylococci and bacilli allows the preferential binding of
branched-chain substrates.
In addition to different straight-chain substrates (see Supple-
mental Results), we analyzed two branched-chain substrate
analogs—trans-5-methyl-2-hexenoyl-CoAand (±)-trans-4-methyl-
2-hexenoyl-CoA—which contain the precursor analog to
the anteiso fatty acids found predominantly in the S. aureus
membrane (Parsons et al., 2011). Among the first-round
substrates (Figure 1), the ratio of specificity constants is approx-
imately 1:24:1 (straight = trans-2-butenoyl-CoA: iso: anteiso)
(Table 3), although the substrate specificity of the anteiso-
substrate may be higher depending on the stereospecificity
of the enzyme. Considering that FabI is the rate-limiting enzyme
in the FAS II pathway (Heath and Rock, 1995), this ratio is
likely to be physiologically significant in determining the compo-
sition of fatty acids synthesized and incorporated into the cell, 802–813, May 9, 2012 ª2012 Elsevier Ltd All rights reserved 809
Table 3. Kinetic Parameters for Wild-Type saFabI Utilizing Various trans-2-Enoyl-CoA Substrates
Km,acyl-CoA (mM)
a kcat (min
1)a kcat/Km,acyl-CoA (min
1 mM1)
trans-2-butenoyl-CoA 1278.3 ± 120.2 40.1 ± 1.8 0.031 ± 0.003
trans-2-hexenoyl-CoA 138.6 ± 18.8 588.3 ± 25.3 4.2 ± 0.6
trans-2-octenoyl-CoA 20.7 ± 2.7 2645.4 ± 107.3 127.8 ± 17.5
trans-2-decenoyl-CoA 29.1 ± 7.5 323.7 ± 29.5 11.1 ± 3.0
trans-5-methyl-2-hexenoyl-CoA (iso-) 307.0 ± 41.5 172.9 ± 8.1 0.56 ± 0.08
(±)-trans-4-methyl-2-hexenoyl-CoA (anteiso-) 599.2 ± 119.1 13.8 ± 1.2 0.023 ± 0.005
See also Figure S1 and Table S3.
aKm,acyl-CoA and kcat values were determined at a fixed NADPH concentration (350 mM).
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entering the FAS II cycle is generated by the branched-chain
specific S. aureus FabH enzyme, the synthesis of BCFAs should
be highly favored in this pathway (see Supplemental Results for
further details) (Qiu et al., 2005). To substantiate the relevance
of this observation, we explored the branched-chain substrate
specificity of the NADH-dependent FabI enzyme from the
gram-negative pathogen F. tularensis (ftFabI). The ratio of spec-
ificity constants (Table S3) for the shortest chain substrates is
approximately 800:72:1 (straight: iso: anteiso) and hence funda-
mentally different from saFabI.
DISCUSSION
Our combined results clearly indicate that saFabI possesses
distinct characteristics that markedly differentiate it from
classical FabI enzymes, while exhibiting similarities to Staphylo-
coccus and Bacillus FabIs and FabL. We identified an RKXXS-
motif, which is responsible for the preferential binding of NADPH
to saFabI and most likely to FabI proteins of other staphylococci
and some Bacillus species. Our analysis also reveals a
fundamental extension of the classical inhibitor binding mecha-
nism including conformational changes in three regions and
a dimer-tetramer transition upon cofactor and inhibitor binding
that may also be applicable for FabI enzymes of related
Staphylococcus and Bacillus species. The oligomeric transition
is coupled to ligand binding and hence may provide the
mechanistic underpinnings for the observed cooperativity
upon substrate binding. Glutamate was shown to influence
cofactor differentiation and to increase the activity of saFabI
while reducing the cooperativity of substrate binding. Never-
theless, cooperativity was still observed at a physiologically
relevant glutamate concentration, suggesting that glutamate
may function as an intracellular metabolite that regulates enzyme
activity (for further details see Supplemental Discussion and
Figure S5).
In contrast to many other bacteria including streptococci, the
cell membranes of Staphylococcus and Bacillus species mainly
comprise branched-chain fatty acids (Balemans et al., 2010;
Brinster et al., 2009; Fozo and Quivey, 2004; Kaneda, 1991;
O’Donnell et al., 1985; Parsons et al., 2011). We propose that
S. aureus FabI, as well as Bacillus FabI and FabL proteins,
have evolved differently compared to classical FabI proteins to
enable the production of BCFAs. The additional flexibility
observed in the saFabI structures and other characterized
Bacillus FabIs may play a role in altering the substrate specificity810 Structure 20, 802–813, May 9, 2012 ª2012 Elsevier Ltd All rightsto accommodate the more bulky branched-chain substrates.
Accordingly, Ser197 in saFabI, which links the two flexible
substrate binding loops after ligand binding (Figure 5G), is
conserved in staphylococci, several bacilli and some Listeria
species. Furthermore, we found that FabI enzymes capable of
utilizing NADPH belong mostly to the BCFA family of organisms;
however, the rationale behind this observation is currently not
clear. To generate a membrane containing mostly branched-
chain fatty acids, S. aureus and B. subtilis FabH enzymes are
known to prefer branched-chain acyl-CoA primers instead of
acetyl-CoA (Figure 1 and Supplemental Results) (Choi et al.,
2000; Qiu et al., 2005). Our data clearly show that this preference
is carried on in the FAS II cycle because the substrate specificity
for the first-round branched-chain substrates relative to the first-
round straight-chain substrate is markedly increased for saFabI
compared to FabIs from organisms producing mainly SCFAs.
Because BCFAs are known to be important for the in vivo
fitness of S. aureus and Listeria monocytogenes (Singh et al.,
2008; Sun andO’Riordan, 2010), the requirement of some organ-
isms for these fatty acids may explain the different susceptibility
of gram-positive bacteria to inhibitors of the fatty acid biosyn-
thesis pathway. Importantly, only a minimal amount of BCFAs
are present in human and murine blood: 1% of all plasma fatty
acids in humans (Holman et al., 1995) and less than 1% in
mice (Atshaves et al., 2005; Gloerich et al., 2005). It is known
that the modulation of membrane lipids enables bacteria to
survive under distinct stress situations (Singh et al., 2008).
Even though both types of fatty acids serve to increase the
fluidity of the membrane bilayer, the structural and morpholog-
ical membrane characteristics differ for BCFAs and UFAs
(Legendre et al., 1980). Hence, compared to UFAs, supplement-
ing with BCFAs did not confer the same level of fitness to
E. coli UFA auxotrophs in response to cold stress (Silbert et al.,
1973). Similarly, other evidence suggests that S. aureus and
L. monocytogenes fitness is reduced in the absence of BCFAs.
The survival of branched-chain a-ketoacid dehydrogenase
(BKD) deficient mutant strains in murine animal models was
significantly reduced (Singh et al., 2008; Sun and O’Riordan,
2010). Nevertheless, future experiments should clarify whether
the defined composition of the human blood lipid pool,
comprisingmainly SCFAs andUFAs, can fulfill the in vivo survival
and virulence requirements of staphylococci and other BCFA
family members (Brinster et al., 2009; Holman et al., 1995).
As the essentiality of the FAS II pathway for S. aureus infection
in vivo is revalidated, a detailed structural and kinetic character-
ization of targets within the pathway becomes increasinglyreserved
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itor discovery efforts. We have shown that the drug target FabI in
S. aureus and closely related pathogens differs from its homolo-
gous proteins with respect to cofactor and substrate specificity,
cofactor/inhibitor binding, and quaternary structure. Knowledge
of these differences, as well as the structures solved here and in
similar studies, can aid in the development of antibiotics specif-
ically targeting FabI enzymes from the important human patho-
gens S. aureus, S. epidermidis, B. anthracis, and B. cereus,
which all synthesize branched-chain fatty acids. Remarkably,
three saFabI inhibitors are in phase I clinical trials since 2009,
providing substantial hope for new MRSA drugs (Gerusz, 2010).
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification
We optimized the saFabI purification protocol with respect to plasmid usage,
E. coli expression strain, cultivation, and buffer composition (see Supple-
mental Experimental Procedures for further details) based on previously
described procedures (Priyadarshi et al., 2010; Xu et al., 2008). A detailed
description of the protocols is provided in Table S4. FtFabI was prepared as
described previously (Lu et al., 2009).
Site-Directed Mutagenesis, Expression, and Purification of saFabI
Mutants
Site-directedmutagenesis was performed using theQuikChangeMutagenesis
Kit fromStratagene to add a single point mutation (S44L) to the previously con-
structed saFabI R40Q/K41N mutant (primers: 50-ACCAGAACGAACGTCTGC
GTAAAGAGCTTGAA-30 and 50-TTCAAGCTCTTTACGCAGACGTTCGTTCTG
GT-30 ) (Xu et al., 2008). The sequence of saFabI R40Q/K41N/S44L was
confirmed by DNA sequencing. Expression and purification of the double
and triple mutant was performed as described in Table S4.
Crystallization, Data Collection, and Structure Determination
Prior to cocrystallization utilizing the vapor diffusion method, purified saFabI
was incubated for 2 hr at 4C with a 10-fold molar excess of NADP+
(100 mg/ml stock solution in water) and a 20-fold molar excess of the respec-
tive inhibitor supplemented as solid powder or dissolved in DMSO (for the P1
structures, 100 mg/ml stock solutions), respectively. The complexes were
crystallized by the hanging drop vapor diffusion method using different precip-
itants (see Supplemental Experimental Procedures). Diffraction data of the
flash-frozen crystals were collected at BESSY II (Berlin) or the ESRF (Greno-
ble), respectively. All structures were solved by molecular replacement with
baFabI (2QIO) as the initial search model (see Supplemental Experimental
Procedures and Tables S1 and S2 for further details).
Analytical Size Exclusion Chromatography
SaFabI was dialyzed into a buffer containing 20 mM Tris (pH 8.0) and 200 mM
NaCl. Equal sample volumes were applied to a calibrated 10/300 Superdex
200 GL column (GE Healthcare) pre-equilibrated with dialysis buffer. Prior to
analytical SEC, the protein (5 mg/ml) was supplemented with a 10-fold molar
excess of NADP+, NADPH, or an equal volume of water and a 20-fold molar
excess of TCL (100 mg/ml stock solution in DMSO) or an equal volume of
DMSO, respectively. All four samples (apo, NADP+, NADPH, and NADP+/
TCL) were incubated at 20C for 2 hr. Experiments were performed in tripli-
cate, and the peak shift was confirmed for a different protein batch at pH
8.0 (Figure S3B). Additionally, one saFabI sample was analyzed at pH 5.6 in
20 mM trisodium citrate (pH 5.6), 500 mM NaCl, and 100 mM EDTA
(Figure S3A).
Synthesis of trans-2-enoyl-CoA Substrates
Trans-5-methyl-2-hexenoic acid and (±)-trans-4-methyl-2-hexenoic acid were
synthesized from isovaleraldehyde (Sigma-Aldrich) and (±)-2-methylbutyral-
dehyde (Sigma-Aldrich), respectively, via a Horner-Wadsworth-Emmons reac-
tion with methyl(triphenylphosphoranylidene)acetate, as described previously
(Ryzhkov, 1996). Trans-2-enoyl-CoA substrates were synthesized from theirStructure 20respective trans-2-enoic acid using the mixed anhydride method (Parikh
et al., 1999). Products were characterized by electrospray ionization mass
spectrometry. Trans-2-butenoyl-CoA was purchased from Sigma-Aldrich.
Steady-State Kinetic Assays
Kinetic experiments were performed on a Cary 100 spectrophotometer
(Varian) at 20C in 50mMpotassium phosphate, 150mMNaCl, and 1Mpotas-
sium glutamate (pH 7.5) containing 8% glycerol (v/v) and 0.1 mg/ml bovine
serum albumin (BSA). Reaction velocities were measured by monitoring the
oxidation of NAD(P)H to NAD(P)+ at 340 nm (ε = 6220 M1 cm1). Kinetic
parameters for saFabI were determined by measuring initial velocities at
varying concentrations of one substrate, holding the other substrate
concentration constant (for further details see Supplemental Experimental
Procedures).
Inhibition Kinetics
Progress curves were used to determine the steady-state inhibition of saFabI
by the slow-onset inhibitors TCL, EPP, and CPP. The final reaction mixture
contained saFabI (100 nM), trans-2-butenoyl-CoA (1.5 mM), NADPH
(350 mM), NADP+ (400 mM), and inhibitor (2% v/v DMSO). Ki*
,app values, corre-
sponding to the final steady-state inhibition following slow isomerization of the
initial enzyme-inhibitor complex, were determined by plotting the fractional
steady-state velocities as a function of inhibitor concentration and fitting to
the standard isotherm equation (Equation 1):
vs
vu
=
1
1+
½I
K;appi
; (1)
where vu is the initial velocity of the uninhibited reaction (for further details see
Supplemental Experimental Procedures).
ACCESSION NUMBERS
The coordinates and structure factors of saFabI in its unliganded form (space
groups P32 and P43212) as well as in complex with NADP
+ and triclosan (space
groups P212121 and P1), CPP, or EPP have been deposited in the PDB with
the codes 4ALN, 4ALM, 4ALL, 4ALI, 4ALJ, and 4ALK, respectively.
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